secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001104659-22-117681
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Leap Therapeutics reports Q3 2022 net loss of $15.1M, up from $11.1M YoY
------------------------------------------------------------------------

- Net loss $15.1M in Q3 2022 vs $11.1M in Q3 2021; R&D expenses $12.1M.
- Cash and equivalents $78.3M at Sept 30, 2022; plus $1.3M R&D incentive receivable.
- Enrolled first patient in Part C of DisTinGuish study (GEA) and DeFianCe study (CRC).
- Presented updated DKN-01 clinical data at ESMO and SITC meetings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465922117681/0001104659-22-117681-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465922117681/tm2230251d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-117681

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer